Author:
Chen Wilfred,Sullivan Millicent O.
Reference30 articles.
1. Biotech products accounted for 35% of all new FDA approvals in 2000–16, in Impact Report: analysis and insight into critical drug development issues. May/June 2017, Tufts Center for the Study of Drug Development
2. Biotech products in Big Pharma clinical pipelines have grown dramatically, in Impact Report: analysis and insight into critical drug development issues. November/December 2013, Tufts Center for the Study of Drug Development
3. Labrijn AF et al (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18(8):585–608
4. Awwad S, Angkawinitwong U (2018) Overview of antibody drug delivery pharmaceutics. 10(3):83
5. Hu Y, Liu C, Muyldermans S (2017) Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Front Immunol 8:1442